OLD Mission Capital LLC Purchases Shares of 111,601 Genmab A/S (NASDAQ:GMAB)

OLD Mission Capital LLC acquired a new stake in Genmab A/S (NASDAQ:GMAB - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 111,601 shares of the company's stock, valued at approximately $2,329,000.

A number of other hedge funds also recently made changes to their positions in GMAB. EverSource Wealth Advisors LLC grew its holdings in Genmab A/S by 295.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company's stock valued at $26,000 after purchasing an additional 939 shares in the last quarter. Lindbrook Capital LLC grew its stake in shares of Genmab A/S by 105.4% during the fourth quarter. Lindbrook Capital LLC now owns 1,851 shares of the company's stock valued at $39,000 after acquiring an additional 950 shares in the last quarter. GAMMA Investing LLC grew its stake in shares of Genmab A/S by 96.6% during the fourth quarter. GAMMA Investing LLC now owns 2,139 shares of the company's stock valued at $45,000 after acquiring an additional 1,051 shares in the last quarter. Cromwell Holdings LLC lifted its stake in shares of Genmab A/S by 656.8% in the fourth quarter. Cromwell Holdings LLC now owns 2,876 shares of the company's stock worth $60,000 after acquiring an additional 2,496 shares in the last quarter. Finally, R Squared Ltd purchased a new position in Genmab A/S in the fourth quarter valued at about $93,000. Hedge funds and other institutional investors own 7.07% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have issued reports on GMAB. BNP Paribas upgraded Genmab A/S from a "strong sell" rating to a "hold" rating in a report on Tuesday, February 11th. Leerink Partners upgraded shares of Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 price target for the company in a research note on Thursday, February 13th. HC Wainwright reiterated a "buy" rating and set a $50.00 price objective on shares of Genmab A/S in a research note on Thursday, January 23rd. Leerink Partnrs raised shares of Genmab A/S from a "hold" rating to a "strong-buy" rating in a research report on Thursday, February 13th. Finally, Sanford C. Bernstein cut shares of Genmab A/S from a "market perform" rating to an "underperform" rating in a research report on Tuesday. One analyst has rated the stock with a sell rating, three have given a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Genmab A/S currently has an average rating of "Moderate Buy" and a consensus price target of $41.33.

Remove Ads

Genmab A/S Trading Up 2.2 %

GMAB traded up $0.42 on Thursday, hitting $19.24. 1,715,372 shares of the company's stock were exchanged, compared to its average volume of 974,158. The stock has a fifty day moving average of $20.72 and a two-hundred day moving average of $21.70. Genmab A/S has a twelve month low of $18.48 and a twelve month high of $30.50. The firm has a market cap of $12.73 billion, a PE ratio of 11.06, a P/E/G ratio of 2.65 and a beta of 0.98.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. On average, analysts predict that Genmab A/S will post 1.45 EPS for the current year.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.